^
Association details:
Biomarker:PD-L1 expression
Cancer:Bladder Cancer
Drug:Imfinzi (durvalumab) (PD-L1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Non Small Cell Lung Cancer)
New
Title:

Imfinzi approved in the EU for less-frequent, fixed-dose use in unresectable non-small cell lung cancer

Excerpt:
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on at least 1% of tumour cells...New option extends dosing from two to four weeks, reducing medical visits and improving patient convenience...
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

Excerpt:
...PD-L1 and VEGF expression assessed in tumor tissue obtained before and after durvalumab instillation`Assessment of PD-L1 and VEGF protein levels in urine samples obtained before and after durvalumab instillation...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder

Excerpt:
...Complete Remission`Overall Survival`Correlate the expression of PD-L1 on immunohistochemistry at pre-treatment and post- durvaRT treatment with DCR...
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A study with patients with non-muscle-invasive bladder cancer that will receive Durvalumab with direct injection in bladder and at the same time some specific molecules named biomarkers will be investigated. Μια μελέτη με ασθενείς με μη μυοδιηθητικό καρκίνο της ουροδόχου κύστης που θα λάβουν το Durvalumab με απευθείας ένεση στην ουροδόχο κύστη και παράλληλα θα μελετηθούν και κάποια ειδικά μόρια που λέγονται βιοδείκτες.

Excerpt:
...PD-L1 and VEGF expression, lymphocyte subpopulations and tumor mutational load will be assessed in tumor tissue obtained before and after durvalumab instillation. ...
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1748P - 4-factor model to predict response and survival benefit with durvalumab (D) in previously treated metastatic urinary tract carcinoma (mUTC)

Published date:
09/05/2022
Excerpt:
In this exploratory retrospective analysis, a 4-factor model composed of readily available factors and comprising tumor PD-L1 expression, visceral metastasis, NLR, and platelet count was associated with improved ORR and OS with D in previously treated pts with progressive mUTC. 
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Correlations Between Progression-free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-analysis

Published date:
06/21/2020
Excerpt:
In a patient-level analysis, data were extracted from available trials of durvalumab...Moderate correlations were observed between ΔORR and OS HR: ITT, -0.63; PD-L1-enriched, -0.53. At the patient level, a positive association was observed between PFS and OS in non-small-cell lung cancer (Kendall's Tau=0.793; 95% confidence interval, 0.789-0.797), head-and-neck squamous-cell carcinoma (0.794; 0.789-0.798), and bladder cancer (0.872; 0.869-0.875).
DOI:
10.1002/cpt.1956